“The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor”. The Journal of Biological Chemistry277 (5): 3622–31. (Feb 2002). doi:10.1074/jbc.M111202200. PMID11723140.
“The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex”. The Journal of Biological Chemistry277 (8): 5734–41. (Feb 2002). doi:10.1074/jbc.M107753200. PMID11714704.
“Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX”. Biochemistry34 (38): 12126–37. (Sep 1995). doi:10.1021/bi00038a005. PMID7547952.
“Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa”. Structure17 (12): 1669–78. (Dec 2009). doi:10.1016/j.str.2009.10.011. PMID20004170.
“Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis”. Thrombosis and Haemostasis67 (1): 63–5. (Jan 1992). doi:10.1055/s-0038-1648381. PMID1615485.
“X-linked thrombophilia with a mutant factor IX (factor IX Padua)”. The New England Journal of Medicine361 (17): 1671–5. (Oct 2009). doi:10.1056/NEJMoa0904377. PMID19846852.
“Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes?”. Interactive Cardiovascular and Thoracic Surgery13 (3): 320–31. (Sep 2011). doi:10.1510/icvts.2011.272401. PMID21712351.
“Factor IX of the blood coagulation system: a review”. Biochemistry. Biokhimiia62 (7): 685–93. (Jul 1997). PMID9331959.
“Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice”. Blood86 (6): 2198–205. (Sep 1995). PMID7662969.
“The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor”. The Journal of Biological Chemistry277 (5): 3622–31. (Feb 2002). doi:10.1074/jbc.M111202200. PMID11723140.
“The factor IXa second epidermal growth factor (EGF2) domain mediates platelet binding and assembly of the factor X activating complex”. The Journal of Biological Chemistry277 (8): 5734–41. (Feb 2002). doi:10.1074/jbc.M107753200. PMID11714704.
“Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX”. Biochemistry34 (38): 12126–37. (Sep 1995). doi:10.1021/bi00038a005. PMID7547952.
“Structural basis of the cofactor- and substrate-assisted activation of human coagulation factor IXa”. Structure17 (12): 1669–78. (Dec 2009). doi:10.1016/j.str.2009.10.011. PMID20004170.
“Characterization of the original Christmas disease mutation (cysteine 206----serine): from clinical recognition to molecular pathogenesis”. Thrombosis and Haemostasis67 (1): 63–5. (Jan 1992). doi:10.1055/s-0038-1648381. PMID1615485.
“X-linked thrombophilia with a mutant factor IX (factor IX Padua)”. The New England Journal of Medicine361 (17): 1671–5. (Oct 2009). doi:10.1056/NEJMoa0904377. PMID19846852.
“Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes?”. Interactive Cardiovascular and Thoracic Surgery13 (3): 320–31. (Sep 2011). doi:10.1510/icvts.2011.272401. PMID21712351.